BB BIOTECH AG / BB Biotech AG earns after-tax profits of CHF 141 million as of September 30, 2015 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its profits of the interim financial statements as of September 30, 2015.
Based on preliminary unaudited consolidated results, BB Biotech AG reports for the nine months period ended September 30, 2015 a profit of CHF 141 million (CHF 744 million in the corresponding period of the previous year). In the third quarter a loss of CHF 575 million (profit of CHF 483 million in the corresponding period of the previous year) was incurred.
The interim report as of September 30, 2015 will be published on October 16, 2015.
For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch
www.bbbiotech.com
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with approx. CHF 3.5 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BB BIOTECH AG via Globenewswire
--- End of Message ---
BB BIOTECH AG
Vordergasse 3 Schaffhausen Switzerland
WKN: AONFN3;ISIN: CH0038389992;
